However, according to the 2022 WHO classification, renal tumors with alterations in the mTOR pathway, particularly biallelic loss of TSC1 or TSC2, are now classified as eosinophilic solid and cystic renal cell carcinoma (ESC-RCC), a distinct entity characterized by mTORC1 pathway activation rather than being considered a subtype of chRCC [17]. The gene discussed is TSC1; the disease is chromophobe renal cell carcinoma.